Back to Search
Start Over
The future of targeted therapy in chronic spontaneous urticaria.
- Source :
-
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology [Ann Allergy Asthma Immunol] 2024 Oct; Vol. 133 (4), pp. 367-373. Date of Electronic Publication: 2024 Jun 15. - Publication Year :
- 2024
-
Abstract
- Chronic urticaria can be divided into 2 subsets: chronic spontaneous urticaria (CSU) with skin lesions occurring without a specific trigger and chronic inducible urticaria, which has an identified specific stimulus. The annual prevalence of chronic urticaria is 0.5% to 2.3% globally. The CSU is a self-limited disorder in most cases, with an average duration of 2 to 5 years, but symptoms persist beyond 5 years in up to 30% of patients. The first line of treatment is a daily nonsedating, second-generation H1-antihistamine. The CSU guidelines recommend using oral nonsedating antihistamines up to 4 fold in patients with CSU unresponsive to standard doses as the next step in treatment. A meta-analysis found that the rate of response in patients with CSU who responded to updosing was 63.2%. Therefore, approximately 40% of patients continue to have persistent hives and itching requiring treatment with the biologic omalizumab, based on evidence from randomized controlled trials. Although omalizumab has been shown to markedly relieve symptoms of CSU, omalizumab is not effective in all patients and has not been shown to induce long-term disease remission. Thus, there is an unmet need for more effective treatments that can lead to cure or long-term remission. In this review, we will provide an overview of new treatment targets and biologics that are under investigation for the treatment of CSU.<br />Competing Interests: Disclosures Dr Saini reports receiving grant, research, and/or clinical trial support from the National Institutes of Health, Novartis, Sanofi, Regeneron, Amgen, Allakos, and Escient and served as a consultant or advisory boards to Allakos, Granular Therapeutics, Novartis, Aquestive, Regeneron, Escient, Innate, Celltrion, and Sanofi. Dr Min has no conflicts of interest to report.<br /> (Copyright © 2024. Published by Elsevier Inc.)
Details
- Language :
- English
- ISSN :
- 1534-4436
- Volume :
- 133
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
- Publication Type :
- Academic Journal
- Accession number :
- 38885835
- Full Text :
- https://doi.org/10.1016/j.anai.2024.05.020